Latest Breaking News On - James william burns - Page 2 : comparemela.com

Agios Pharmaceuticals, Inc to Post Q2 2025 Earnings of ($1 62) Per Share, Zacks Research Forecasts (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc to Post Q2 2025 Earnings of ($1 62) Per Share, Zacks Research Forecasts (NASDAQ:AGIO)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJames william burnsJacqualyna fouseGoldman sachs groupSecurities exchange commissionCantor fitzgeraldRoyal bankNorges bankDimensional fund advisorsAgios pharmaceuticalsJpmorgan chase coNews ratings for agios pharmaceuticals dailyAgios pharmaceuticals incZacks researchFrazier life sciences managementAgios pharmaceuticals trading down

The Goldman Sachs Group Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33 00

The Goldman Sachs Group Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJames william burnsJacqualyna fouseJpmorgan chase coNews ratings for agios pharmaceuticals dailyAgios pharmaceuticalsChina universal asset management coCharles schwab investment management incDeutsche bankRoyal bankMirae asset global investments coAgios pharmaceuticals stock performanceAgios pharmaceuticals incCantor fitzgeraldInsider activity at agios pharmaceuticalsGoldman sachs group

Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 39.74% and a negative net margin of 1,199.26%. The company […]

United statesJames william burnsBrian goffNews ratings for agios pharmaceuticals dailySecurities exchange commissionRoyal bankAgios pharmaceuticals trading downAgios pharmaceuticals incCantor fitzgeraldAgios pharmaceuticalsJpmorgan chase coEarnings history for agios pharmaceuticalsAgios pharmaceuticals company profileGoldman sachs groupGet free reportPharmaceuticals trading down

Agios Pharmaceuticals (NASDAQ:AGIO) Issues Earnings Results, Beats Estimates By $0 19 EPS

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had […]

United statesBrian goffJames william burnsInsider activity at agios pharmaceuticalsGoldman sachs groupCantor fitzgeraldAgios pharmaceuticals trading downJpmorgan chase coRoyal bankSecurities exchange commissionAgios pharmaceuticals incAgios pharmaceuticalsNews ratings for agios pharmaceuticals dailyEarnings history for agios pharmaceuticalsGet free reportPharmaceuticals trading down

Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.19, Briefing.com reports. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals […]

United statesJames william burnsBrian goffAgios pharmaceuticals incRoyal bankGoldman sachs groupNews ratings for agios pharmaceuticals dailyAgios pharmaceuticalsCantor fitzgeraldAgios pharmaceuticals trading downAgios pharmaceuticals company profileEarnings history for agios pharmaceuticalsJpmorgan chase coGet free reportPharmaceuticals trading downAgios pharmaceuticals daily